51
|
Xie W, Zuo J, Ma Z, Yu W, Hu Z, Yang T, Song Z. The Burden of Colorectal Cancer Attributable to Diet Low in Fiber from 1990 to 2019: A Global, Regional and National Analysis. J Nutr Health Aging 2022; 26:1061-1069. [PMID: 36519769 DOI: 10.1007/s12603-022-1865-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
OBJECTIVES The colorectal cancer (CRC) burden is increasingly high. The aim of this study was to investigate temporal and geographical trends in CRC deaths and disability-adjusted life-years (DALYs) attributable to diet low in fiber globally from 1990 to 2019. DESIGN Cross-sectional study. SETTING The study based on the Global Burden of Disease Study (GBD) 2019. PARTICIPANTS The population comprised individuals from 204 countries and territories who were diagnosed with CRC attributable to diet low in fiber from 1990 to 2019. MEASUREMENTS Deaths, DALYs, age-standardized mortality rates (ASMR), and age-standardized DALY rates (ASDR) for CRC attributable to diet low in fiber were described, and estimated annual percentage change (EAPC) was further calculated to assess the burden in different regions, countries, sexes, and age groups. Additionally, we explored the association between EAPC and ASMR/ASDR (in 1990) and Human Development Index (HDI, in 2019). RESULTS From 1990 to 2019, global ASMR and ASDR for CRC attributable to diet low in fiber decreased slightly, but the corresponding deaths and DALYs increased by 63.37% and 51.36%, respectively. Those burden varied considerably between regions and countries. The burden was higher in high, high-middle and middle SDI regions, especially in Asia and Western Europe, but when HDI > 0.7, an increasingly rapid decline in ASMR and ASDR was revealed. Unexpectedly, many less well-developed countries within the traditionally low deaths and DALYs regions of Africa, Central Latin America, and Middle East showed gradual increases in ASMR and ASDR. CONCLUSION The global burden of CRC attributable to diet low in fiber has decreased over the last 30 years, but remains at a high level. It is essential for decision-makers to take targeted measures for improving population awareness and intake of dietary fiber.
Collapse
|
52
|
Ma Z, Ma C. Series representations and simulations of isotropic random fields in the Euclidean space. THEORY OF PROBABILITY AND MATHEMATICAL STATISTICS 2021. [DOI: 10.1090/tpms/1158] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
This paper introduces the series expansion for homogeneous, isotropic and mean square continuous random fields in the Euclidean space, which involves the Bessel function and the ultraspherical polynomial, but differs from the spectral representation in terms of the ordinary spherical harmonics that has more terms at each level.The series representation provides a simple and efficient approach for simulation of isotropic (non-Gaussian) random fields.
Collapse
|
53
|
Jiang H, Shang X, Zhang C, Yue J, Duan X, Ma Z, Chen C, Zhang W, Pang Q, Zhang W, Liu L, Ren X, Meng B, Zhao G, Zhang P, Wei Y, Ma Y, Zhang L, Li Y. 166TiP Pembrolizumab combined with neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy followed surgery for locally advanced esophageal squamous cell carcinoma: Protocol for a multi-center, prospective, randomized-controlled, phase III clinical study (Keystone-002). Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.10.185] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
54
|
Shang X, Zhang C, Zhao G, Zhang W, Liu L, Duan X, Yue J, Ma Z, Chen C, Meng B, Ren X, Jiang H. LBA3 Safety and efficacy of pembrolizumab combined with paclitaxel and cisplatin as a neoadjuvant treatment for locally advanced resectable (stage III) esophageal squamous cell carcinoma (Keystone-001): Interim analysis of a prospective, single-arm, single-center, phase II trial. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.10.218] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
55
|
Yang X, Men Y, Wang J, Kang J, Sun X, Zhao M, Sun S, Yuan M, Bao Y, Ma Z, Wang G, Hui Z. Adjuvant Radiotherapy is Safe and Effective for Patients with T1b-SM2 Esophageal Carcinoma After Endoscopic Resection – A Second Analysis From a Pilot Study. Int J Radiat Oncol Biol Phys 2021. [DOI: 10.1016/j.ijrobp.2021.07.455] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
56
|
Yang W, Su S, Ouyang W, Ma Z, Chen X, Li H, Lu B. To Evaluate the Efficiency and Safety of Nab-paclitaxel Plus Cisplatin and Concomitant Thoracic Radiotherapy in Locally Advanced Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 2021. [DOI: 10.1016/j.ijrobp.2021.07.1290] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
57
|
Wang J, Ma X, Shang K, Wu S, Ma Y, Ma Z, Cao B. Safety and efficacy of spleen aminopeptide oral lyophilized powder for improving quality of life and immune response in patients with advanced breast cancer: a multicenter, randomized, double-blind, placebo-controlled clinical trial. Anticancer Drugs 2021; 32:1067-1075. [PMID: 34261911 PMCID: PMC8517102 DOI: 10.1097/cad.0000000000001109] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2021] [Revised: 05/30/2021] [Indexed: 12/03/2022]
Abstract
Health-related quality of life (HRQoL) is an important consideration in managing patients. Spleen aminopeptide oral lyophilized powder (SAOLP) has been used to enhance cellular immunity in a patient. This multicenter, randomized, double-blind, placebo-controlled clinical trial was designed to evaluate the safety and efficacy of SAOLP for improving HRQoL in patients with breast cancer. Patients diagnosed with advanced breast cancer were included, and were administered SAOLP or placebo 4 mg qd for two cycles. The primary endpoint was improvement in HRQoL on day 42 measured by the EORTC QLQ-C30 and EORTC QLQ-BR23. Secondary endpoints included immunologic function, improvement in HRQoL on day 21 and 84, objective response rate, disease control rate, BMI and adverse events. On day 42, on the EORTC QLQ-C30 or EORTC QLQ-BR23, scores on the functional scales and QoL scale were significantly higher and scores on symptom scales were significantly lower in patients who received SAOLP compared to placebo (P < 0.05). On day 84, the number of CD3, CD4 and CD8 cells were significantly higher in patients who received SAOLP. There were no significant differences in objective response rate, disease control rate or BMI. SAOLP may improve HRQoL and the immune response in patients with advanced breast cancer, represents a convenient and safe adjuvant therapy.
Collapse
|
58
|
Sun S, Zou L, Wang T, Liu Z, He J, Sun X, Zhong W, Zhao F, Li X, Li S, Zhu H, Ma Z, Wang W, Meng J, Zhang F, Hou X, Wei L, Hu K. Age ≥60 y May Not be an Appropriate Adverse Risk Factor in Adjuvant Treatment of Patients With Early-Stage Endometrial Carcinoma: A Multi-Institutional Analysis in China. Int J Radiat Oncol Biol Phys 2021. [DOI: 10.1016/j.ijrobp.2021.07.1681] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
59
|
Wang H, Li M, Xing R, Wei C, Ma Z. P48.10 Efficacy of EGFR-TKIs vs TKIs Plus Chemotherapy as First-Line Treatment in EGFR-Mutation Lung Adenocarcinoma With Liver Metastases. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.08.521] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
60
|
Wang H, Xing R, Li M, Zhang M, Zhang G, Zhang X, Ma Z. P48.08 The Efficacy and Clinical Survival Outcome of Different First-Line Treatments in EGFR Mutant Non-Small Cell Lung Cancer With Brain Metastases. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.08.519] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
61
|
Zhou C, Xiong A, Miao L, Chen J, Li K, Liu H, Ma Z, Wang H, Lu Z, Shen J, Zhao J, Li W, Bi M, Zhang J, Xing L. P51.03 Oritinib (SH-1028), a Third-generation EGFR-TKI in Advanced NSCLC Patients with Positive EGFR T790M: Results of a Single-arm Phase Ib Trial. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.08.540] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
62
|
Zhou C, Wang Z, Sun Y, Cao L, Ma Z, Wu R, Yu Y, Yao W, Wang H, Chen J, Zhuang W, Cui J, Chen X, Lu Y, Shen H, Chen R, Xu X, Lu D, Wang J, Yang J. MA13.07 GEMSTONE-302: A Phase 3 Study of Platinum-Based Chemotherapy with Placebo or Sugemalimab, a PD-L1 mAb, for metastatic NSCLC. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.08.180] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
63
|
Wu L, Wu Z, Xiao Z, Ma Z, Weng J, Chen Y, Cao Y, Cao P, Xiao M, Zhang H, Duan H, Wang Q, Li J, Xu Y, Pu X, Li K. P48.01 Anlotinib Plus Docetaxel vs Docetaxel for 2nd-Line Treatment of EGFR negative NSCLC (ALTER-L018): A Randomized Phase II Trial. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.08.512] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
64
|
Wang H, Wei C, Zhang G, Zhang M, Yan X, Zhang X, Niu Y, Yang J, Ma Z. P16.06 Comparison of Clinical Outcomes of Patients With Advanced NSCLC In Clinical Trials and in the Real World Received PD-1/PD-L1 Inhibitor. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.08.345] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
65
|
Ren S, He J, Fang Y, Chen G, Ma Z, Chen J, Guo R, Lin X, Yao Y, Wu G, Wang Q, Zhou C. MA13.01 Camrelizumab Plus Apatinib in Treatment-Naive Patients With Advanced Non-Squamous NSCLC: A Multicenter, Open-Label, Single-Arm, Phase 2 Trial. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.08.175] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
66
|
Ma Z, Ning B, Wu D, Liu WG, Guo YJ. Correlation between culprit vessel/tirofiban and reperfusion bradyarrhythmia in patients with ST-segment elevation myocardial infarction after emergency PCI. EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES 2021; 25:5137-5144. [PMID: 34486688 DOI: 10.26355/eurrev_202108_26526] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
OBJECTIVE To evaluate the correlation between culprit vessel/tirofiban and reperfusion bradyarrhythmia in patients with ST-segment elevation myocardial infarction (STEMI) after emergency percutaneous coronary intervention (PCI). PATIENTS AND METHODS A total of 123 STEMI patients undergoing emergency PCI in our hospital from September 2018 to September 2019 were selected and divided into the reperfusion arrhythmias (RA) group (50 cases) and non-RA group (NRA, 73 cases) according to whether RA occurring during PCI. The baseline data such as age and underlying disease were statistically analyzed. Then, the differences were compared between the two groups. According to whether reperfusion bradyarrhythmia (RB) occurring during PCI, 123 STEMI patients were divided into the RB group (63 cases) and non-RB group (60 cases). The relation between culprit vessel/tirofiban and RB was analyzed. ROC curves analysis and multivariate logistic regression were conducted for the risk factors of RA and RB. RESULTS Among 123 patients with STEMI after PCI treatment, 73 patients had RA (59.35%), including RB 63 cases and tachyarrhythmia 10 cases. Results of single factor analysis showed that there was statistical significance in 3 factors including the patient age, infarction area and vascular blood flow TIMI classification between RA group and NRA group (p<0.05). ROC curve analysis indicated that the continuous variable patent ages had predictive value in the prevalence of RA, which resulting in an AUC 0.624 and a cut-off pointed age 57 (sensitivity 72.60, specificity 52.00). Multivariate regression analysis showed that the patient age (>57 years old), infarction area in inferior wall and grade 0 lesion vascular blood flow TIMI classification in RA group was significantly higher than that in NRA group (p<0.05). Tirofiban was not associated with RB in STEMI patients treated with emergency PCI, while culprit vessel was statistically significant between RB group and NRB group (p<0.05). Multivariate regression analysis indicated that culprit vessel of the right coronary artery and grade 0 lesions vascular blood flowed TIMI classification was independent risk factors to occurring RB in the STEMI patients with emergency PCI. CONCLUSIONS Tirofiban was not associated with RB in STEMI patients treated with emergency PCI. However, it may increase the risk of RB development when the culprit vessel is the right coronary artery. Therefore, timely corresponding treatments and reduction of reperfusion damage are of great significance for those patients.
Collapse
|
67
|
Gao B, Ma Z, Yu X, Huang D, Zhao J, Day D, Body A, Zhou Q, Chu Q, Pan H, Cui J, Chen C, Xiang X, Fei C, Yang L, Wu YL. 1284P Sitravatinib + tislelizumab in patients with anti-PD-(L)1 refractory/resistant metastatic NSCLC. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1886] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
68
|
Shen L, Lu ZH, Wang JY, Shu YQ, Kong L, Yang L, Wang BH, Wang ZW, Ji YH, Cao GC, Liu H, Cui TJ, Li N, Qiu WS, Ma Z, Chen YL, Li HY, Sun X, Wang Y, Zhou H. LBA52 Sintilimab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced or metastatic esophageal squamous cell cancer: First results of the phase III ORIENT-15 study. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.2132] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
69
|
Zhou X, Liu X, Yang X, Wang L, Hong Y, Lian K, Qiu G, Shang X, Ma Z, Yuan H, Hu F. Tumor progress intercept by intervening in Caveolin-1 related intercellular communication via ROS-sensitive c-Myc targeting therapy. Biomaterials 2021; 275:120958. [PMID: 34130142 DOI: 10.1016/j.biomaterials.2021.120958] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2020] [Revised: 04/30/2021] [Accepted: 06/04/2021] [Indexed: 12/24/2022]
Abstract
Tumor-associated macrophages (TAMs) in the tumor microenvironment (TME) play an important role in the development of tumors by secreting a variety of cytokines or directly communicating with tumor cells, making TAMs-targeted therapeutic strategies very attractive. It has been reported that oncogene c-Myc is related to every aspect of the oncogenic process of tumor cells and the alternative activation of macrophages. Hence, we constructed a glycolipid nanocarrier containing ROS-responsive peroxalate linkages (CSOPOSA) for ROS-triggered release of drugs and further modified it with Ex 26 (Ex 26-CSOPOSA), a selective sphingosine 1-phosphate receptor 1 (S1PR1) antagonist, to achieve the dual-targeted delivery of the c-Myc inhibitor JQ1 via S1PR1, which is overexpressed on both tumor cells and TAMs, thereby inducing apoptosis of tumor cells, and blocking M2 polarization of macrophages. More strikingly, our studies found that JQ1 could effectively inhibit the migration of tumor cells induced by M2 macrophages-derived exosomes via blocking Caveolin-1 related intercellular exosome exchange through lncRNA H19 and miR-107. The in vivo results revealed that this dual-targeted delivery strategy effectively inhibited tumor growth and metastasis with less systemic toxicity, providing a potential method for effective tumor treatment.
Collapse
|
70
|
Ma Z, Lu C, Zhu J, Cheng X, Tuo B, Liu X, Li T. Upregulation of SLC26A9 resulted in the development and progression of HER2-positive breast cancer via activating PI3 K/ AKT signaling pathway. Breast 2021. [DOI: 10.1016/s0960-9776(21)00108-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
71
|
Zhou C, Xiong A, Li W, Ma Z, Li X, Fang J, Xie Q, Fan Y, Xu J, Van H, Kong P, Yang F, Li J, Lu Y, Xu T. P77.03 A Phase II Study of KN046 (Bispecific Anti-PD-L1/CTLA-4) in Patients (pts) with Metastatic Non-Small Cell Lung Cancer (NSCLC). J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.1161] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
72
|
Ma Z, Zhang Y, Huang Q, Chen H. P02.09 Comprehensive Investigation of Resected Benign Lesions Suspected for Lung Cancer: Implications for Avoiding Unnecessary Pulmonary Resection. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.357] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
73
|
Cheng Y, Wu L, Ma Z, Liu C, Huang Y, Liu Y, Liu X, Lei G, Zhou N, Bai Y, Yu H. P48.08 Phase IV Clinical Study on the Safety and Efficacy of Lobaplatin-Based Regimen With Small Cell Lung Cancer. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.878] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
74
|
Zhang M, Wang H, Ma Z, Zhang X, Zhang G, Li P, Yan X. P87.03 Characteristics and Outcomes of RET-Rearranged Non-Small Cell Lung Cancer from China: A Retrospective Study of Real-World. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.1258] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
75
|
Shi Y, Hu X, Liao W, Zhang S, Wang Z, Yang N, Wu L, Zhou J, Ying K, Ma Z, Feng J, Liu L, Qin S, Fang J, Zhang X, Jiang Y, Ge N. P76.65 CNS Efficacy of AST2818 in Patients with T790M-Positive Advanced NSCLC: Data from a Phase I-II Dose-Expansion Study. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.1122] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|